November 28, 2022

Matthew L. Daniel Corporate Senior Vice President, General Counsel, Corporate Secretary & Chief Compliance Officer Charles River Laboratories International, Inc. 251 Ballardvale Street Wilmington, MA 01887

## Via UPS Next Day Air Saver

Dear Mr. Daniel:

Attached to this letter is a shareholder proposal submitted for inclusion in the Charles River Laboratories International, Inc. proxy statement for the 2023 annual meeting. Also enclosed is a letter from People for the Ethical Treatment of Animals' (PETA) brokerage firm, RBC Wealth Management, confirming the requisite common stock ownership, which PETA intends to hold at least this amount through and including the date of the 2023 shareholders meeting.

PETA is available to meet in person or via teleconference within 10-30 calendar days from the date of this letter, including the following in EST:

- 12/12: 1-2 p.m. & 4-5 p.m.
- 12/13: 2-3 p.m. & 3:30-5 p.m.
- 12/14: 12-1 p.m. & 4-5 p.m.
- 12/15: 2-4 p.m.
- 12/16: 12-2 p.m. & 4-5 p.m.

If there are any issues with this proposal being included in the proxy statement or if you need any further information, please contact PETA's authorized representative Jared Goodman at 2154 W. Sunset Blvd., Los Angeles, CA 90026, +1 (323) 210-2266 or JaredG@PetaF.org.

Sincerely,

CariEdans

Carrie Edwards, Executive Assistant PETA Corporate Responsibility

Enclosures: 2023 Shareholder Proposal RBC Wealth Management letter PEOPLE FOR THE ETHICAL TREATMENT OF ANIMALS

PETA

## Washington

1536 16th St. N.W. Washington, DC 20036 202-483-PETA

### Los Angeles

2154 W. Sunset Blvd. Los Angeles, CA 90026 323-644-PETA

Norfolk

501 Front St. Norfolk, VA 23510 757-622-PETA

Info@peta.org PETA.org

#### Entities:

- PETA Asia
- PETA India
- PETA France
- PETA Australia
- PETA Germany
- PETA Switzerland
  PETA Netherlands
- FETA Internetionas
- PETA Foundation (U.K.)

200 Park Avenue, 2nd Floor FLORHAM PARK, NJ 07932



November 28, 2022

Tracy Reiman Executive Vice President People for the Ethical Treatment of Animals 501 Front Street Norfolk, VA 23510

Re: Verification of Shareholder Ownership in Charles River Laboratories International, Inc.

Dear Ms. Reiman,

This letter verifies that People for the Ethical Treatment of Animals Inc. (PETA) is the beneficial owner of 22 shares of Charles River Laboratories International, Inc. common stock. As of November 28, 2022, PETA holds and has held continuously for at least three years 13 shares of Charles River Laboratories International, Inc. common stock.

Should you have any questions or require additional information, please contact me at (408) 947-3322.

Sincerely,

Inle All

Jenilee Hill, APP Senior Registered Client Associate RBC Wealth Management

Investment and insurance products: • Not insured by the FDIC or any other federal government agency • Not a deposit of, or guaranteed by, the bank or an affiliate of the bank • May lose value

# Report on the Importation of Nonhuman Primates Into the U.S. and the Transport of Nonhuman Primates Within the U.S.

**RESOLVED**, that the Board report to shareholders annually on the species, country of origin (including wild-caught or captive-bred, omitting proprietary information), and numbers of nonhuman primates imported by the company into the U.S.; the species and numbers of nonhuman primates transported within the country; and measures the company is taking to mitigate its impact on dwindling populations in nature.

# **Supporting Statement**

Our company moves thousands of monkeys every year on U.S. highways, often over thousands of miles. Federal law requires that a veterinarian examine monkeys transported across state lines within 10 days prior to shipment. In July 2022, the USDA cited our company for transporting monkeys from its Reno facility to the University of Utah without proper veterinary inspections required under the federal Animal Welfare Act.<sup>1</sup>

Our company's failure to conduct timely veterinary inspections, along with the company's previously reported issues with infectious diseases,<sup>2</sup> jeopardizes public health and safety. Imported monkeys can carry tuberculosis, deadly diarrheal pathogens, West Nile virus, malaria, herpes B, and other diseases and infectious agents that are transmissible to humans.

The threat is significant: In January 2022, after a truck carrying 100 monkeys crashed in Pennsylvania, three monkeys escaped and were shot on orders of the Centers for Disease Control and Prevention (CDC), as they posed a public health risk. Transporting monkeys across the U.S.—particularly when federal laws are broken—could harm our company's reputation and business. It is in the company's interest that it be transparent with its shareholders about the extent of its monkey transport within the U.S.

Our company is one of the largest importers of nonhuman primates into the U.S.—bringing in thousands of monkeys each year from Southeast Asia and Mauritius. The majority of these primates are of the species *Macaca fascicularis* (also known as "long-tailed macaques"). According to the CDC, 95% of the 92,430 monkeys brought into the U.S. during fiscal years 2019 to 2021 were long-tailed macaques.

The international trade in long-tailed macaques is steeped in violence, and widespread laundering of wild-caught animals as captive-bred is evident in recent indictments brought by the Department of Justice.<sup>3</sup> These activities have a devastating impact on wild populations. In July 2022, the International Union for Conservation of Nature (IUCN) changed the conservation status of long-tailed macaques from "vulnerable" to "endangered"—and cited the voracious experimentation industry in the U.S. as a major factor in the species' dramatic population crash.<sup>4</sup> The IUCN projects an additional population decline of 50% over the next three generations if

<sup>&</sup>lt;sup>1</sup>https://www.peta.org/wp-content/uploads/2022/09/USDA\_Inspection\_Report\_Charles-River-Laboratories-Inc-8.pdf

<sup>&</sup>lt;sup>2</sup><u>https://ir.criver.com/node/23391/html</u>

<sup>&</sup>lt;sup>3</sup>https://www.internationalprimatologicalsociety.org/harvesting-of-wild-primates-for-use-in-biomedical-research/ <sup>4</sup>https://www.iucnredlist.org/species/12551/199563077

current threats aren't mitigated. Our company cannot remain linked to this biodiversity and ethical catastrophe—it is crucial that our company inform shareholders of measures it is taking to lessen its impact on populations of long-tailed macaques, as this division of our company's business could suffer considerably if the company fails to be proactive.

We urge our fellow shareholders to support this responsible resolution.